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Abstract
Background: Rift Valley fever is an emerging zoonotic viral disease, enzootic and endemic in Africa and the
Arabian Peninsula, which poses a significant threat to both human and animal health. The disease is most severe in
ruminants causing abortions in pregnant animals, especially sheep animals and high mortality in young populations.
High mortality rates and severe clinical manifestation have also been reported among camel populations in Africa, to
attend however none of the currently available live vaccines against RVF have been tested for safety and efficacy in this
species. In this study, the safety and efficacy (through a neutralizing antibody response) of the thermostable live
attenuated RVF CL13T vaccine were evaluated in camels in two different preliminary experiments involving 16 camels,
(that 12 camels and 4 pregnant camels).
Results: The study revealed that the CL13T vaccine was safe to use in camels and no abortions or teratogenic effects
were observed. The single dose of the vaccine stimulated a strong and long-lasting neutralizing antibody response for
up to 12 months.
Conclusion: The presence of neutralization antibodies is likely to correlate with protection; however protection would
need to be confirmed by challenge experiments using the virulent RVF virus.
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Background
Rift Valley fever (RVF) is a zoonotic viral disease caused
by Rift Valley fever virus (RVFV), which is a virus within
the genus Phlebovirus and family Bunyaviridae. RVF is
enzootic and endemic in Africa, Saudi Arabia and
Yemen and poses a significant threat to both human and
animal health [1–3]. The disease is most severe in sheep,
goats and cattle, causing abortions in pregnant females
and high mortality in young animals [4–8].
Vaccination is considered to be the most effective way
to prevent and control the expansion of the disease.
However, the available attenuated vaccines for RVF
cause abortions and teratogenic effects (Smithburn
strain vaccine) or are thermolabile (CL13 strain vaccine)
[6, 9, 10]. An evaluation of efficacy and safety of the
CL13 vaccine in ewes at different stages of pregnancy
indicated that the vaccine did not induce clinical mani-
festation of RVF, such as abortion in pregnant ewes,
teratogeny in their offspring or pyrexia in vaccinated
animals [11]. Vaccination with CL13 vaccine also pre-
vented clinical RVF following virulent challenge. A re-
cent study carried out by Daouam et al. [12] revealed
that the CL13 vaccine strain was unstable in both lyoph-
ilized and liquid forms at 22–25 °C and at 37 °C, which
highlight the importance of cold chain when using the
CL13 vaccine in endemic tropical countries. In response
to this need, the CL13 vaccine strain was made thermo-
stable through three cycles of heating (56 °C) and selec-
tion of thermostable particles (12). The thermostable
vaccine clone (CL13T) was found to be safe when tested
on sheep, goats and cattle with no clinical signs or side
effects observed. Neutralizing antibodies were detected in
vaccinated animals for a minimum of one year in sheep
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and goats, and for at least 4 months in cattle indicating
that the vaccine also provide a good protection [12].
Recent outbreaks of RVF in western Africa have re-
sulted in high mortality and severe clinical signs among
dromedary camel populations [13]. Serological surveys
in northern and eastern Africa have revealed high per-
centages of seropositive camels after the occurrence of
an outbreak [14, 15]. Camels are therefore susceptible to
RVFV, and are likely to play a role in the epidemiology
of the disease and should be included in any vaccination
program. There have been no previous reports of camels
being vaccinated against RVF, and no RVF vaccines in-
cluding a thermostablized vaccine have been tested for
safety and efficacy in this species. This study therefore
was conducted to evaluate the safety and efficacy of the
thermostable live attenuated CL13T vaccine in camels.
Methods
Vaccine (CL13T) production and titration
The CL13T attenuated virus was propagated and titrated
on African Green monkey kidney cells (Vero, ATCC)
[9]. The vaccine was formulated by mixing V/V the viral
suspension with a stabilizer of lyophilisation (4 % pep-
tone, 8 % sucrose and 2 % glutamate). The viral suspen-
sion titre is fixed to have a minimum of 106 DICT50 per
dose. The RVF CL13T vaccine was distributed in glass
vials and freeze dried. Before administration, the vaccine
was reconstituted by adding a saline solution.
Safety and efficacy testing of the CL13T candidate
vaccine in camels
All experiments involving camels (Camelus Dromedar-
ius) were carried out in accordance with guidelines for
the care and handling of experimental animals these ani-
mals are dedicated to research and maintained an ex-
perimental farm. The animal experiments were approved
by the MCI ethics committee in charge of the control
and supervision of experiments on animals and the ex-
periments were conducted in high containment level 3
facilities. Sixteen dromedary’s camels 2–3 year old, nega-
tive for RVFV antibody by the neutralization test were
divided in two groups of six and one group of 4.
In experiment 1: Two groups of 6 camels were vacci-
nated subcutaneously (SC) with a dose of 106 TCID50 of
the CL13T vaccine. Camels in group 1 received a single
dose of the vaccine and camels of group 2 received a
booster dose, four weeks after the first vaccination. The
general behavior and rectal temperature of the camels
were recorded daily for two weeks after each vaccination
as well as observation for local inflammation at the in-
jection site. Sera samples were obtained daily for the first
15 days post-vaccination (PV) and tested for RVFV RNA
and infectious virus by quantitative real-time PCR [16]
and virus isolation in Vero cells, respectively. Antibody
titers were monitored over a 12 months period by virus-
neutralization (VN) on Vero cell culture as described in
the OIE manual (OIE, 2012). VN was performed on 96
wells plates using 100 DL50 of the RVFV (CL13) per well
with a serial 3 fold dilution of the serum in a 4 wells rep-
licate foe each dilution. After 60 mn of neutralization at
37 °C, the cells suspension was added and the plate in-
cubated 5 days before reading. The neutralizing titre is
determined by Reed et Muench method and expressed
in log10/ml. Sera were also tested for IgG detection by a
competitive ELISA (ID-VET RIFTC-4P).
In experiment 2: a group of 4 pregnant she camels
were vaccinated via the SC route with a 10X the normal
dose (107 TCID50) of the CL13T vaccine. Rectal temper-
atures, appetite and behavior of each animal were docu-
mented daily for 1 month and then every month during
five months after vaccination until calving for a potential
abortions effect and teratogenicity.
Statistical analysis
The antibody titers detected in the first and second
group of camels were compared using the Student t test;
with a significance level of p = 0.05.
Results
Safety testing of CL13T candidate vaccine in camels
The C13T vaccine was found to be safe, with no evidence
of abortions or teratogenicity among the offsprings of the
vaccinated pregnant camels. All camels were healthy and
did not have any sign of illness. Normal body tempera-
tures were recorded in the pregnant as well as among the
camels in Group 1 and 2 before vaccination and no local
reactions were recorded at the injection sites. In the
15 days after vaccination no abnormal behavior was ob-
served in any of the vaccinated animals and their body
temperatures remained in the normal range. Very low
levels of viral RNA (Cycle Threshold values from 37.6 to
38.6 among a total of 40 cycles) were detected in the blood
of 7 of the camels in Groups 1 and 2 during the first
2 weeks following vaccination. However, no infectious
virus was isolated from the samples after 2 blind passages
on Vero cells. The absence of RVFV in the inoculated cells
was confirmed by qPCR.
Serological responses in camels vaccinated with the
CL13T candidate vaccine virus
Neutralizing antibody were recorded in all the vacci-
nated camels by day 12 PV, with peak neutralizing titers
of 2.5 log DN50 (equivalent to a serum dilution of 1:500)
being observed on day 28 (PV) (Fig. 1). High titers of
neutralizing antibody were maintained for a period of
6 months PV, at which time the titers started to wane
over the next 6 months, reaching at titer of 0.92 log
DN50 (equivalent to a serum dilution of 1:10) at twelve
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months post-vaccination (Fig. 1). Similar antibody titers
were detected in camels vaccinated once (group 1) and
twice (group 2), showing that there was no significant
increase in neutralizing antibody titers through the ad-
ministration of a booster dose of the vaccine.
Significant differences (p < 0.05) in antibody titers were
observed in the sera samples from camels tested by VN
as compared to those tested by cELISA. Antibody titers
measured by the two tests (VN and cELISA) remained
similar for the first 3 months post-vaccination and then
diverged to attain titers that were significantly different
(Fig. 2). Results revealed a reduced sensitivity of the
cELISA compared to the VN test for the detection of
RVFV antibody (Fig. 2). It is important to note however
that the cELISA kit used in this study has only been vali-
dated for use in ruminants. Thus, results indicate that
this cELISA may not be optimized for use in camels and
that the sensitivity of the assay may need to be improved
before it can be recommended for routine diagnosis or
for vaccination monitoring in camels.
Discussion
This study reveals that camels mounted a strong and long-
lasting neutralizing antibody response when vaccinated
with a single dose of the live CL13T RVF vaccine and that
the vaccine is safe to use, producing no significant side-
effects in the vaccinated animals. The neutralizing antibody
response was similar to that observed in small ruminants
and cattle after vaccination with the live RVF clone 13 vac-
cine [17, 18].
This is the first report that evaluates the safety and ef-
ficacy of a live attenuated thermostabilized RVF vaccine
in camels. To be sure that this vaccine protects camels
against RVF, challenge studies would need to be carried
out. However in the case of RVF, neutralizing antibodies
are known to be reliable predictor of protection after
vaccination [17, 19]. The high levels of neutralizing anti-
bodies observed in the vaccinated camels may indicate
therefore that the CL13T vaccine is likely to be protect-
ive in camels for up to 12 months.
It is highly recommended to vaccinate livestock to
prevent the occurrence of disease in susceptible ani-
mals and if possible virus amplifying hosts, in order
to break the epidemiological transmission cycle. With
the high densities of dromedary camels in many areas
where RVF is present, it is extremely important to be
able to protect camels, as well as other susceptible
species.
Fig. 1 Neutralizing antibody titres in camels vaccinated with a single and a double dose of live CL13T RVF vaccine. All camels were vaccinated
subcutaneously (SC) with a dose of 106TCID50 of the CL13T vaccine. Camels in group 1 received a single dose and camels of group 2 received a
booster at day 30 after vaccination
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This is the first study that has evaluated the safety and
immunogenicity of a live attenuated RVF vaccine in
camels. A recent study, reported camel vaccination with
a recombinant adenovirus encoding RVFV envelope
glycoprotein. A lower antibody neutralizing titre was ob-
served in camels comparatively to other species (sheep,
goats and cattle) with a dose of 109 injected intramuscu-
larly in the presence of an adjuvant [19]. No challenge
was carried out for the protection testing.
Conclusions
In our study, the obtained antibody response in vacci-
nated camels was similar to that registered in sheep and
better than cattle response with a dose of 106 only,
injected by S/C route. Although this is a preliminary
study, the presence of neutralization antibodies is likely
to correlate with protection. To be noted that RVF pro-
tection of camels has never been tested by experimental
infection and no challenge model has been developed
for camels.
In summary, the study showed that the CL13T live at-
tenuated vaccine is safe to use in camels and that a single
dose of the vaccine stimulated strong and long-lasting
neutralizing antibody response for up to 12 months. In
the absence of any tested live vaccine for camels, the
CL13T vaccine could be considered for camel protection
against RVF after a field trial that include sufficient num-
ber of animals under the normal living conditions.
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